JPMorgan Says Buy the Dip in These 2 Large-Cap Biotech Stocks
View original at finance.yahoo.comO que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Investors should be buying Alnylam Pharmaceuticals on the dip
60% confidenceSeveral important trends are developing simultaneously within large-cap biotech, including improving profitability, broader commercial diversification, a steady flow of clinical catalysts, and continued business development opportunities
60% confidenceThe biotech sector could see additional dealmaking activity in the coming quarters, creating a favorable backdrop for large-cap biotech stocks
60% confidenceMultiple biotech companies have either recently transitioned to sustained profitability or are approaching that milestone in the near term, with room for margins to expand further
60% confidenceAlnylam Pharmaceuticals has secured a Strong Buy consensus rating from the broader analyst community
60% confidenceThe large-cap biotech group is broadly at an inflection point, with a growing number of companies converting pipeline success into durable, profitable commercial franchises
60% confidence